
|Articles|June 13, 2022
- 2022 OTC Guide
Gastroesophageal Reflux Disease
Author(s)Saro Arakelians, PharmD
Most individuals can manage the discomfort of GERD with lifestyle changes and OTC medications.
Advertisement
Insights:
- Many individuals experience acid reflux from time to time.
- Gastroesophageal reflux disease (GERD) is mild acid reflux that occurs at least twice a week or moderate to severe acid reflux that occurs at least once a week.
- Most individuals can manage the discomfort of GERD with lifestyle changes and OTC medications. But some individuals with GERD may need stronger medications or surgery to ease symptoms.
- Symptoms may include a burning sensation in the chest usually after eating, chest pain, difficulty swallowing, regurgitation of food or sour liquid, and the sensation of a lump in the throat.
- Risk factors may include certain foods, connective tissue disorders, delayed stomach emptying, eating large meals, obesity, pregnancy, or smoking.
- Diagnosis tools include ambulatory acid probe test, esophageal manometry, upper endoscopy, and x-ray.
- Treatment includes antacids such as Mylanta, Rolaids, and Tums. They also include medications such as H2-receptor blockers cimetidine (Tagamet), famotidine (Pepcid), and nizatidine (Axid). Proton pump inhibitors may also be used, such as Prevacid and Prilosec.
Articles in this issue
almost 4 years ago
Pharmacy Clinical Pearl: Geographic Tonguealmost 4 years ago
Pharmacy Times is Leading the Wayalmost 4 years ago
Seize the Opportunity to Help Those Who Need Special OTC Counselingalmost 4 years ago
26 Years Strongalmost 4 years ago
Caffeine and Chocolate Consumption May Trigger Migrainesalmost 4 years ago
Help Patients Manage Cold and Flu Symptomsalmost 4 years ago
Pharmacy Clinical Pearl: Cold SoresAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Paradigm Shift in Lipid Management: Highlights from the NLA 2026 Scientific Sessions Opening Session
2
ATTR-CM Red Flags, Treatment Evidence, and the Pharmacist's Role in Care
3
Staging the Heart: NLA and EAS Reveal a New Era of Precision Lipidology and Imaging
4
FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant Treatment of High-Risk Clear Cell RCC
5


































































































































